Navigation Links
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Date:10/26/2008

rse events observed were consistent with expectations for the treatment-experienced HIV-infected population. Importantly, the incidence of malignancy seen across the vicriviroc clinical program has not increased over time even as the cumulative exposure to vicriviroc has increased by numbers of patients and duration of treatment.

"These long-term results demonstrate that vicriviroc added to an optimized background therapy may provide durable viral suppression and sustained elevated CD4 counts in treatment-experienced HIV-infected patients," said Jihad Slim, M.D., division of infectious diseases, Saint Michael's Medical Center, Newark, N.J., and an investigator for the vicriviroc clinical program. "Importantly, vicriviroc was well tolerated, with some patients continuing on treatment for up to four years, and it was not associated with increased liver, CNS or cardiovascular adverse events or with an increased incidence of malignancy in this patient population."

About the Data Analysis

Patients enrolled in the Phase II vicriviroc VICTOR-E1 study(3) (including patients in the placebo arm) and the ACTG 5211 study(4) were eligible to continue on open-label vicriviroc with optimized background therapy at the completion of 48 weeks of treatment in an extension for each study. The vicriviroc dose for all patients was escalated to 30 mg once daily during the open-label treatment period. As there were no dose-related differences in the safety profile, data for all patients receiving vicriviroc were pooled for analysis regardless of the original starting vicriviroc dose. The mean duration of vicriviroc treatment for all patients (N=205) was 96 weeks (range 1-216 weeks).

Analyses were performed on data from all patients who completed at least 12 weeks of vicriviroc treatment (N=196). Virologic response to regimens containing vicriviroc was evidenced within 12 weeks by a significant decrease in virus (HIV RNA) detectable in the blood and was sustained
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... -- Haemonetics Corporation (NYSE: HAE ) announced today that ... present at The East Coast IDEAS Investor Conference in ... , 2015 at 2:30pm Eastern time.  ... webcast at: http://www.wsw.com/webcast/threepa16/hae About ... global healthcare company dedicated to providing innovative blood management ...
(Date:5/26/2015)... -- Depomed, Inc. (NASDAQ: DEPO ) today announced that ... The 2015 Jefferies Healthcare Conference in New ... for 3:00 pm EDT (12:00 noon PDT) Tuesday, June 2, ... Conference in New York City.  The presentation at the JMP ... Wednesday, June 24, 2015. Both presentations will be ...
(Date:5/26/2015)... , England and PITTSBURGH , May ... a leading global pharmaceutical company, today announced that Mylan ... the Bernstein Strategic Decisions Conference, Friday, May 29, 2015 ... can access a live webcast of the presentation via ... http://mylan.com/investors . An archived version will also be available ...
Breaking Medicine Technology:Depomed To Present At Healthcare Conferences In June 2
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) today announced ... at upcoming major medical meetings. The,data will ... QUADRAMET(R),(samarium Sm-153 lexidronam injection) in combination settings ... from prostate,cancer and multiple myeloma, as well ...
... of,In-Segment Late Loss, Non-Inferiority in Major Secondary Endpoint,of Target ... in the SPIRIT III U.S. Trial -, ABBOTT PARK, ... Abbott's SPIRIT III U.S. pivotal clinical,trial at the of ... following key results: , , -- ...
Cached Medicine Technology:New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 2New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 3New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 4New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 5Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 2Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 3Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 4Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 5
(Date:5/26/2015)... Octo Consulting Group (Octo), an award-winning ... to the federal marketplace, has named Gaurav “GP” Pal ... this newly created role, Pal will be responsible for ... computing, big data, and digital services. , “We’re excited ... we continue to bring clients new and innovative solutions ...
(Date:5/26/2015)... May 26, 2015 Relias Learning ... for the health and human services market, announces expansion ... demand. After strong attendance and participation in 2014, they ... give their annual user conference an exciting new facelift. ... to come together and discuss best practices, share their ...
(Date:5/26/2015)... Pasadena, CA (PRWEB) May 26, 2015 ... is now offering complimentary dental cleanings with cosmetic treatments. ... , Cosmetic Dentistry , “We are committed ... giving you cutting-edge technology, outstanding customer service and a ... not only to change your smiles but to change ...
(Date:5/26/2015)... National Prevention Week , National Prevention Week ... supported by the Substance Abuse and Mental Health Services ... and action about, substance abuse as well as mental ... encouraged to join in promoting prevention strategies, in educating ... in building community partnerships. , The Voice of One, ...
(Date:5/26/2015)... York, NY (PRWEB) May 26, 2015 Award-winning ... for a good cause. "The photography show will connect viewers ... in their lives.” For the last five years, Raul has ... to convey the notion that we are not bounded by ... a language spoken in Raul’s native country, Bolivia. The photo ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group (Octo) Appoints Gaurav “GP” Pal as Vice President of Technology Strategy and Cloud Solutions 2Health News:Relias Learning Expands User Groups and Industry Influence 2Health News:Relias Learning Expands User Groups and Industry Influence 3Health News:Pasadena Porcelain Veneers Expert, Marine Martirosyan DDS, is Now Offering Complimentary Dental Cleaning with Cosmetic Treatments 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:A Photographer & Two Educational Organiazations Join to Make a Difference in Our Youth 2
... Time" a Valuable Present: Peake, WASHINGTON, Dec. 21 ... volunteers who remember our nation,s,veterans, especially those hospitalized in ... "Some of our patients will be unable to ... B. Peake, Secretary of Veterans Affairs. "The,good cheer and ...
... research suggests , FRIDAY, Dec. 21 (HealthDay News) -- Treating ... concludes a University of Pennsylvania School of Medicine study in ... , It found that providing depression care management to older ... over five years by about 50 percent. , "Depression is ...
... for ambulatory care ... ... Cardiac Science,Corporation, (Nasdaq: CSCX ), a leading provider of ... of its HeartCentrix(R) ECG informatics software with Greenway,Medical Technology,s PrimeSuite(R) ...
... Milk Processors and, Bally Total Fitness to Shape Up ... ... SILVER SPRING, Md., Dec. 21 Discovery Health,s fifth,annual NATIONAL ... biggest and best year yet, with online registration beginning on,December ...
... costs of providing comprehensive screening and diagnostic services to ... or cervical cancer for treatment. Dr. Donatus U. Ekwueme ... Health Promotion at the Centers for Disease Control and ... cost of screening a woman for breast cancer was ...
... 20 ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), ... Drug,Application (NDA) to the U.S. Food and Drug ... seeking approval for Xibrom QD,as a treatment for ... (bromfenac ophthalmic solution), Xibrom is a topical ...
Cached Medicine News:Health News:VA Salutes Volunteers' Spreading Holiday Cheer 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 3Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 4Health News:Discovery Health's Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle 2Health News:Discovery Health's Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle 3Health News:Study determines costs of breast and cervical cancer detection among low-income women 2Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2
... Ergonomic Design for Unparalleled Comfort Pick one ... the balance. Notice the trigger and ejector positionsright ... because our pipettors are ergonomically designed to help ... of pipetting. Productivity In The Palm Of ...
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... Pick one of our pipettors up and ... and ejector positionsright where they should beeven if ... designed to help avoid repetitive stress injuries caused ... The Palm Of Your Hand Start dispensing ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... tip ejection with long, lever tip ejector ... , Accepts universal tips or for greater ...
Medicine Products: